Euclidean Capital LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Euclidean Capital LLC reported 10 stock positions worth $795.8 million. Its top holding was SS SPDR S&P 500 ETF Trust-US (SPY) at 78.4% of the portfolio, followed by iShares MSCI India ETF (INDA, 17.0%) and Foghorn Therapeutics (FHTX, 1.1%). Compared with Q1 2024, it sold out of 2 and added to 1. The biggest buy was SS SPDR S&P 500 ETF Trust-US (SPY, shares +18%) and the biggest sale an exit from SPDR Gold Shares (GLD).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001825034
- Portfolio Value
- $795.8M (Q2 2024)
- SEC Filing
- 0001012975-24-000328 ↗ filed Aug 14, 2024
Holdings Value
Holdings 10 stocks · $795.8M
| SPY SS SPDR S&P 500 ETF Trust-US | 78.43% | 1,146,979 | $624.2M | Add +17.7% |
| INDA iShares MSCI India ETF | 17.00% | 2,425,144 | $135.3M | No change |
| FHTX Foghorn Therapeutics Inc. | 1.14% | 1,573,761 | $9.0M | No change |
| ORIC Oric Pharmaceuticals Inc. | 0.88% | 989,410 | $7.0M | No change |
| ALEC Alector Inc. | 0.75% | 1,307,858 | $5.9M | No change |
| PMVP PMV Pharmaceuticals Inc. | 0.53% | 2,627,643 | $4.3M | No change |
| 23ANDME HOLDING CO | 0.50% | 10,243,122 | $4.0M | No change |
| TNYA Tenaya Therapeutics Inc. | 0.40% | 1,015,705 | $3.1M | No change |
| RAPT THERAPEUTICS INC | 0.25% | 657,899 | $2.0M | No change |
| SRZN Surrozen Inc. | 0.12% | 87,696 | $960K | No change |
Other holdings (1): bonds, preferreds, convertibles and warrants · $3K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| SRZNW Surrozen Inc.-CW25 | *W EXP 08/01/203 | 170,833 | $3K | No change |
Total filed on the 13F, all lines: $795.8M.
Portfolio Sells Q1 2024 → Q2 2024
Portfolio Buys Q1 2024 → Q2 2024
| SPY SS SPDR S&P 500 ETF Trust-US | Add +17.7% | 78.43% | +13.07 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 10 | $439.8M | VEU, VTV, INDA, ORIC, TMS |
| Q1 2026 | 9 | $392.3M | VEU, VTV, INDA, ORIC, FHTX |
| Q4 2025 | 11 | $369.4M | VEU, VTV, INDA, FHTX, ORIC |
| Q3 2025 | 10 | $238.0M | VEU, INDA, ORIC, FHTX, ALEC |
| Q2 2025 | 10 | $305.7M | VEU, INDA, ORIC, FHTX, PMVP |
| Q1 2025 | 10 | $266.1M | INDA, VEU, FHTX, ORIC, PMVP |
| Q4 2024 | 10 | $736.7M | SPY, INDA, VEU, ORIC, FHTX |
| Q3 2024 | 11 | $906.8M | SPY, INDA, VEU, FHTX, ORIC |
| Q2 2024 | 10 | $795.8M | SPY, INDA, FHTX, ORIC, ALEC |
| Q1 2024 | 12 | $780.0M | SPY, INDA, GLD, ORIC, FHTX |